HIV therapeutic vaccines: moving towards a functional cure

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 1-8

  Mylvaganam, Geetha H ^a,b   Silvestri, Guido ^a,b   Amara, Rama Rao ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PD 1 ANTIBODY; PGT 121; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG EFFICACY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRAL CLEARANCE; VIREMIA; VIRUS CARRIER; VIRUS REPLICATION; ADOPTIVE TRANSFER; ANIMAL; B LYMPHOCYTE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; HIV; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84929404465     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.05.001     Document Type: Review

References (69)

1. Barouch D.H., Michael N.L. Accelerating HIV-1 vaccine efficacy trials. Cell 2014, 159:969-972.
2. Hunt P.W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9:139-147.
3. Jilek B.L., Zarr M., Sampah M.E., Rabi S.A., Bullen C.K., Lai J., Shen L., Siliciano R.F. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 2012, 18:446-451.
4. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
5. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
6. Kapogiannis B.G., Henderson S.L., Nigam P., Sharma S., Chennareddi L., Herndon J.G., Robinson H.L., Amara R.R. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort. AIDS Res Hum Retroviruses 2006, 22:272-282.
7. Whitney J.B., Hill A.L., Sanisetty S., Penaloza-MacMaster P., Liu J., Shetty M., Parenteau L., Cabral C., Shields J., Blackmore S., et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014, 512:74-77.
8. Lori F., Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 2001, 286:2981-2987.
9. Nacsa J., Stanton J., Kunstman K.J., Tsai W.P., Watkins D.I., Wolinsky S.M., Franchini G. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology 2003, 305:210-218.
10. Oxenius A., Price D.A., Gunthard H.F., Dawson S.J., Fagard C., Perrin L., Fischer M., Weber R., Plana M., Garcia F., et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 2002, 99:13747-13752.
11. Ortiz G.M., Wellons M., Brancato J., Vo H.T., Zinn R.L., Clarkson D.E., Van Loon K., Bonhoeffer S., Miralles G.D., Montefiori D., et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001, 98:13288-13293.
12. Lori F., Lewis M.G., Xu J., Varga G., Zinn D.E., Crabbs C., Wagner W., Greenhouse J., Silvera P., Yalley-Ogunro J., et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000, 290:1591-1593.
13. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J., Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
14. Klatt N.R., Shudo E., Ortiz A.M., Engram J.C., Paiardini M., Lawson B., Miller M.D., Else J., Pandrea I., Estes J.D., et al. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 2010, 6:e1000747.
15. Mueller Y.M., Do D.H., Boyer J.D., Kader M., Mattapallil J.J., Lewis M.G., Weiner D.B., Katsikis P.D. CD8+ cell depletion of SHIV89.6P-infected macaques induces CD4+ T cell proliferation that contributes to increased viral loads. J Immunol 2009, 183:5006-5012.
16. Okoye A., Park H., Rohankhedkar M., Coyne-Johnson L., Lum R., Walker J.M., Planer S.L., Legasse A.W., Sylwester A.W., Piatak M., et al. Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J Exp Med 2009, 206:1575-1588.
17. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
18. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S., Louie L., Eron J., Sheppard H., Frelinger J.A. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses 1999, 15:1219-1228.
19. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81:8468-8476.
20. Deng K., Pertea M., Rongvaux A., Wang L., Durand C.M., Ghiaur G., Lai J., McHugh H.L., Hao H., Zhang H., et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 2015, 517:381-385.
21. Perreau M., Savoye A.L., De Crignis E., Corpataux J.M., Cubas R., Haddad E.K., De Leval L., Graziosi C., Pantaleo G. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013, 210:143-156.
22. Xu Y., Weatherall C., Bailey M., Alcantara S., De Rose R., Estaquier J., Wilson K., Suzuki K., Corbeil J., Cooper D.A., et al. Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 2013, 87:3760-3773.
23. Mylvaganam G.H., Velu V., Hong J.J., Sadagopal S., Kwa S., Basu R., Lawson B., Villinger F., Amara R.R. Diminished viral control during simian immunodeficiency virus infection is associated with aberrant PD-1hi CD4 T cell enrichment in the lymphoid follicles of the rectal mucosa. J Immunol 2014, 193:4527-4536.
24. Soghoian D.Z., Jessen H., Flanders M., Sierra-Davidson K., Cutler S., Pertel T., Ranasinghe S., Lindqvist M., Davis I., Lane K., et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012, 4:123ra125.
25. Gauduin M.C., Yu Y., Barabasz A., Carville A., Piatak M., Lifson J.D., Desrosiers R.C., Johnson R.P. Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med 2006, 203:2661-2672.
26. Chehimi J., Campbell D.E., Azzoni L., Bacheller D., Papasavvas E., Jerandi G., Mounzer K., Kostman J., Trinchieri G., Montaner L.J. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801.
27. Grassi F., Hosmalin A., McIlroy D., Calvez V., Debre P., Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 1999, 13:759-766.
28. Donaghy H., Pozniak A., Gazzard B., Qazi N., Gilmour J., Gotch F., Patterson S. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001, 98:2574-2576.
29. Pacanowski J., Kahi S., Baillet M., Lebon P., Deveau C., Goujard C., Meyer L., Oksenhendler E., Sinet M., Hosmalin A. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98:3016-3021.
30. Soumelis V., Scott I., Gheyas F., Bouhour D., Cozon G., Cotte L., Huang L., Levy J.A., Liu Y.J. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001, 98:906-912.
31. Ramirez L.A., Arango T., Boyer J. Therapeutic and prophylactic DNA vaccines for HIV-1. Expert Opin Biol Ther 2013, 13:563-573.
32. Fuller D.H., Rajakumar P.A., Wu M.S., McMahon C.W., Shipley T., Fuller J.T., Bazmi A., Trichel A.M., Allen T.M., Mothe B., et al. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 2006, 348:200-215.
33. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., Felber B.K., Tartaglia J., Pavlakis G.N., Franchini G. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002, 169:4778-4787.
34. De Rose R., Fernandez C.S., Smith M.Z., Batten C.J., Alcantara S., Peut V., Rollman E., Loh L., Mason R.D., Wilson K., et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 2008, 4:e1000055.
35. Hel Z., Venzon D., Poudyal M., Tsai W.P., Giuliani L., Woodward R., Chougnet C., Shearer G., Altman J.D., Watkins D., et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000, 6:1140-1146.
36. Walker B.D., Hirsch M.S. Antiretroviral therapy in early HIV infection. N Engl J Med 2013, 368:279-281.
37. Fuller D.H., Rajakumar P., Che J.W., Narendran A., Nyaundi J., Michael H., Yager E.J., Stagnar C., Wahlberg B., Taber R., et al. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 2012, 7:e33715.
38. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
39. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., Oswald K., Shoemaker R., Li Y., Lewis M.S., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
40. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003, 9:27-32.
41. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10:1359-1365.
42. Garcia F., Climent N., Guardo A.C., Gil C., Leon A., Autran B., Lifson J.D., Martinez-Picado J., Dalmau J., Clotet B., et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013, 5:166ra162.
43. Levy Y., Thiebaut R., Montes M., Lacabaratz C., Sloan L., King B., Perusat S., Harrod C., Cobb A., Roberts L.K., et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol 2014, 44:2802-2810.
44. Montefiori D.C., Morris L., Ferrari G., Mascola J.R. Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS 2007, 2:169-176.
45. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., Stephenson K.E., Chang H.W., Shekhar K., Gupta S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228.
46. Shingai M., Nishimura Y., Klein F., Mouquet H., Donau O.K., Plishka R., Buckler-White A., Seaman M., Piatak M., Lifson J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013, 503:277-280.
47. Yang L., Wang P. Passive immunization against HIV/AIDS by antibody gene transfer. Viruses 2014, 6:428-447.
48. Ondondo B.O. The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol 2014, 5:439.
49. van Gils M.J., Sanders R.W. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013, 435:46-56.
50. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
51. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., Desrosiers R.C., Clark K.R. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
52. Gardner M.R., Kattenhorn L.M., Kondur H.R., von Schaewen M., Dorfman T., Chiang J.J., Haworth K.G., Decker J.M., Alpert M.D., Bailey C.C., et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015, 519:87-91.
53. Petrovas C., Price D.A., Mattapallil J., Ambrozak D.R., Geldmacher C., Cecchinato V., Vaccari M., Tryniszewska E., Gostick E., Roederer M., et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007, 110:928-936.
54. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
55. Velu V., Kannanganat S., Ibegbu C., Chennareddi L., Villinger F., Freeman G.J., Ahmed R., Amara R.R. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007, 81:5819-5828.
56. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., Palmer S., Brockman M., Rathod A., Piechocka-Trocha A., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007, 8:1246-1254.
57. Cecchinato V., Tryniszewska E., Ma Z.M., Vaccari M., Boasso A., Tsai W.P., Petrovas C., Fuchs D., Heraud J.M., Venzon D., et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008, 180:5439-5447.
58. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009, 182:5891-5897.
59. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
60. Khaitan A., Unutmaz D. Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011, 8:4-11.
61. Corbeau P., Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011, 117:5582-5590.
62. Lori F., Maserati R., Lisziewicz J., Minoli L. Immune reconstitution and control of HIV. HIV Clin Trials 2004, 5:170-182.
63. Mavigner M., Cazabat M., Dubois M., L'Faqihi F.E., Requena M., Pasquier C., Klopp P., Amar J., Alric L., Barange K., et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 2012, 122:62-69.
64. Sheth P.M., Chege D., Shin L.Y., Huibner S., Yue F.Y., Loutfy M., Halpenny R., Persad D., Kovacs C., Chun T.W., et al. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol 2008, 1:382-388.
65. Mehandru S., Poles M.A., Tenner-Racz K., Jean-Pierre P., Manuelli V., Lopez P., Shet A., Low A., Mohri H., Boden D., et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006, 3:e484.
66. Pallikkuth S., Micci L., Ende Z.S., Iriele R.I., Cervasi B., Lawson B., McGary C.S., Rogers K.A., Else J.G., Silvestri G., et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS Pathog 2013, 9:e1003471.
67. Sandler N.G., Bosinger S.E., Estes J.D., Zhu R.T., Tharp G.K., Boritz E., Levin D., Wijeyesinghe S., Makamdop K.N., del Prete G.Q., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511:601-605.
68. Siliciano J.D., Siliciano R.F. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol 2014, 134:12-19.
69. Dahabieh M.S., Battivelli E., Verdin E. Understanding HIV latency: the road to an HIV cure. Annu Rev Med 2015, 66:407-421.